NEW FUNCTIONS OF CLASSICAL HORMONE, α-MELANOPHORE-STIMULATING HORMONE

Yoshikazu Tonosaki¹⁾, Yasuo Sugiura²⁾ and Eric W. Roubos³⁾

Abstract It is well-known that a-melanophore-stimulating hormone (a-MSH) release from the amphibian pars intermedia (PI) depends on the light condition of the animal's background. In the present study, we present two new functions of a-MSH in amphibians and mammals. In *Xenopus laevis*, we show that temperatures below 8 °C stimulate a-MSH secretion of the PI and skin darkening, with a maximum at 5 °C, under regulation of the hypothalamus rule, independently from the illumination state of the background. The cold-induced a-MSH release of the PI was inhibited by neuropeptide-Y-producing suprachiasmatic-melanotrope-inhibiting neurons in the ventrolateral area of the suprachiasmatic nucleus but increasely in thyrotropin-releasing-hormene-containing neurons of the magnocellular nucleus. It is known that intracerebroventricular (ICV) administration of a low dose of interleukin-1 β (IL-1 β) induces hyperalgesia inducing IL-1 β and the site of a-MSH concerned, we have examined Fos expression in the brain in response to ICV microinjection of a-MSH and/or IL-1 β . Following injection of 10 pg IL-1 β , hyperalgesia was induced and Fos became expressed in the paraventricular nucleus (PVN) of the hypothalamus and in the arcuate nucleus (ARC), which contains a-MSH-producing neurons. ICV co-injection of IL-1 β with 30 ng a-MSH fully inhibited both hyperalgesia and Fos expression in the PVN and the ARC. We conclude that PVN neurons are activated by hyperalgesic IL-1 β and propose that this effect is abolished by a-MSH released from the ARC but not from the pituitary gland.

Hirosaki Med. J. 59, Supplement : S202-S209, 2007

Key words: *a*-melanophore-stimulating hormone (*a*-MSH); low temperature; Fos; hyperalgesia; interleukin-1 β (IL-1 β)

Introduction

In this review, we summarize two studies on new roles of classical hormone a-MSH in amphibians and mammals. It is well-known that a-melanophore-stimulating hormone (a-MSH) is released from the neuroendocrine melanotrope cells in the pars intermedia (PI) of the amphibian pituitary gland and regulates the dispersion of melanin in skin melanophores during the process of skin color adaptation to the light condition

¹⁾ Department of Anatomical Science, Hirosaki University Graduate School of Medicine, Hirosaki, Aomori, Japan of the background¹⁻³⁾. This process is neurally regulated by several neurochemical messengers originating in the brain and by autocrine factors produced by the melanotropes, as was shown in much detail especially in the toad *Xenopus laevis*, the frog *Rana ridibunda* and *Rana nigromaculata*¹⁻¹⁷⁾. In addition to light, low temperature seems to influence amphibian skin color but the role of temperature in the functioning of the PI is poorly understood^{18,19)}. Firstly as a new function of *a*-MSH, we present detailed information on the

Phone: +81-172-33-5111/ext 6016, Fax: +81-172-39-5006, E-mail: tonosaki@cc.hirosaki-u.ac.jp

²⁾ Department of Functional Anatomy and Neuroscience, Nagoya University Graduate School of Medicine, Nagoya, Japan

³⁾ Department of Cellular Animal Physiology, Institute for Neuroscience, Radboud University Nijmegen, Nijmegen, The Netherlands.

effects of low temperature on skin color adaptation and on *a*-MSH release from the PI of *Xenopus laevis*. Also, we report on regulatory system that is responsible for the low temperatureinduced *a*-MSH release from the PI, using double fluorescence immunohistochemistry for Fos as an indicator for neural and cellular activity^{20,21}.

In mammals, *a*-MSH-containing neurons, nerve fibers and cells exist in several parts of the brain and in the $PI^{22\cdot24}$ whereas *a*-MSH does not play an important role in skin color control. These facts are full of interesting suggestions on new functions of *a*-MSH in mammals. Secondly we present a role of *a*-MSH as host defense modulator in rat, that is, inhibitory effects of *a*-MSH on interleukin-1 β -induced hyperalgesia and neural activation in the paraventricular nucleus (PVN) and the arcuate nucleus (ARC) of the rat, using Fos immunohistochemistry.

1. Low temperature stimulates α-MSH secretion and inhibits background adaptation in *Xenopus laevis* [Refer to 25 for details]

In the present study, we carried out nine experiments on the effect of low temperature on this skin adaptation process in the toad Xenopus *laevis*, using the skin melanophore index (MI) bioassay and an *a*-MSH radioimmunoassay (RIA) to measure skin color adaptation and α -MSH secretion respectively^{17,26,27)}. Although measuring the MI does not provide direct data on the concentration of α -MSH in the blood, there is a direct and log-linear relationship between the MI and the a-MSH plasma content as measured by RIA²⁸. Compared with in vitro RIA, the in vivo MI bioassay has prominent features in Xenopus laevis, that is, the relative MSH contents in same animal can be measured easily and continually in conventional laboratory condition^{17,26-29)}. We show that temperatures below 8°C stimulate a-MSH secretion and skin darkening, with a maximum at 5° C,



Figure 1 *a*-MSH release from the pars intermedia (PI) of *Xenopus laevis* in a cold environment were estimated by Δ MIs, after 3 h stay at various temperatures. Δ MIs by the *in vivo* MI bioassay reflect plasma *a*-MSH concentrations.



Figure 2 Plasma a-MSH concentrations of nontreated (Nt) and NIL-extirpated (NILx) toads on a white background, after 3 h stay at different temperatures (22°C, 5°C, 0°C), measured by RIA. Means±SD. *P<0.05, **P<0.01, ***P<0.001. NS no significant difference. Number of animals (N) is indicated on top of each column.

independently from the illumination state of the background (Figure 1).

No significant stimulatory effect of low temperature on the MI and a-MSH plasma contents was noted when the experiment was repeated with toads from which the neurointermediate lob (NIL) had been surgically extirpated (Figure 2).

This indicates that low temperature stimulates a-MSH release from melanotrope cells located

Y. Tonosaki, et al.



Figure 3 Percental changes in Fos-immunoreactivity of NPY-containing neurons in ventrolateral area of SC (SC-VL) and of TRH-containing neurons in Mg, at control temperature (22°C) and after 3 days of cold exposure (5°C). Means±SD.
**P<0.01. NS not significant. Number of animals (N) is indicated on top of each column.

in the PI. An in vitro superfusion study with the NIL demonstrated that low temperature does not act directly on the PI^{25,30)}. A possible role of the central nervous system in coldinduced α -MSH release from the PI was tested by studying the hypothalamic expression of Fos and the coexistence of Fos with the regulators of melanotrope cell activity, neuropeptide Y (NPY) and thyrotropin-releasing hormone (TRH), using double fluorescence immunohistochemistry. Upon lowering temperature from 22 to 5 °C, in whiteadapted animals Fos expression decreased in NPY-producing suprachiasmatic-melanotropeinhibiting neurons (SMIN) in the ventrolateral area of the suprachiasmatic nucleus (SC) but increased in TRH-containing neurons of the magnocellular nucleus (Mg) (Figure 3).

We conclude that temperatures around 5 $^{\circ}$ C inactivate the SMIN in the SC and activate TRH-neurons in the Mg, resulting in enhanced *a*-MSH secretion from the PI, darkening the skin of white-adapted *Xenopus laevis* (Figure 4).



Figure 4 Hypothetic scheme of the regulation of *a*-MSH release from melanotrope cells in the pars intermedia (PI) of *Xenopus laevis* in a cold environment, via TRH and NPY, in a sagittal plane through the brain and pituitary gland. DM; dorsomedial area of SC, Mg; magnocellular nucleus, PD; pars distalis, PI; pars intermedia, PN; pars nervosa, SC; suprachiasmatic nucleus, VL; ventrolateral area of SC.

2. α-MSH antagonizes interleukin-1βinduced hyperalgesia and Fos-expression in the paraventricular and arcuate nucleus of the rat [Refer to 31 for details]

Interleukin-1 β (IL-1 β) plays an important role in immunoregulation and also mediates nonspecific host-defense responses such as fever and sensory response distortion³²⁻³⁴⁾. In rat, intracerebroventricularly (ICV) administered IL-1 β induces hyperalgesia when given in a low, non-pyrogenic concentration (10 pg/ kg to 1 ng/kg), and fever in a higher, nonhyperalgesic concentration $(100 \text{ ng/kg})^{35-37)}$. ICV administration of a pyrogenic dose of IL-1 β also stimulates the expression of the Fos protein, a marker for cellular activity²¹, in neurons of the paraventricular nucleus (PVN) of the hypothalamus³⁸⁻⁴³⁾, suggesting that pyrogenic IL- 1β activates PVN neurons. However, the target of hyperalgesia-inducing IL-1 β in the central nervous system (CNS) is unknown. While, from physiological experiments on rats, it has been

S 204



Figure 5 Paw lick latency time in hot-plate test, 0, 30, 60 and 90 min after ICV-microinjection with saline (S; N=5), 10 pg/animal IL-1 β (10; N=5), 100 ng/animal IL-1 β (100; N=6), 10 pg/animal IL-1 β +30 ng/animal *a*-MSH (10+M; N=6) and 30 ng/animal *a*-MSH (M; N=5). Means ± S.E.M. Asterisks indicate significant difference with each of the four other groups, at P≤0.05.

concluded that *a*-MSH inhibits hyperalgesia induced by ICV injection of IL-1 β , but the site of *a*-MSH release concerned is not known.

Here, we study the possible involvement of pituitary *a*-MSH and of *a*-MSH present in the brain²²⁻²⁴⁾ in the antagonism of hyperalgesic IL- 1β in rat, focusing on Fos expression in the PVN, in the arcuate nucleus (ARC), containing *a*-MSH neurons, and in the *a*-MSH-producing melanotrope cells in the PI.

Materials and Methods

Adult male Wister rats (age 8-16 weeks; 250-330 g) implanted a stainless steel guide cannula into the left lateral cerebral ventricle (LCV) for microinjection of *a*-MSH and/or IL-1 β , were housed under standard laboratory conditions with food and water freely available. The effects of drug injection on algesia were determined using a hot-plate test to estimate the degree of sensory distortion as a measure for hyperalgesia^{35-37,44,45}. A rat was placed on the plate, heated to 51.5±0.5 °C, and the time until the first avoidance response (paw lick latency time) was determined. The target of



Figure 6 Fos-positive neuronal nuclei (arrows) in the total PVN, 90 min after ICV-administration of saline (a), 10 pg/animal IL-1 β (b; IL-1 β), 10 pg/animal IL-1 β +30 ng/animal a-MSH (c; IL-1 β +a-MSH) or 30 ng/animal a-MSH (d; a-MSH). Inset in b shows detail of Fospositive nuclei. Scale bar=100 μ m.

hyperalgesia-inducing IL-1 β was investigated by immunohistochemistry for Fos (ABC-DAB method) as an indicator for cellular activity. The number of Fos-immunoactive neurons or cells in the PVN, ARC and PI were counted using Nikon drawing tube.

Results and Discussion

Hyperalgesia induced by IL-1 β (Figure 5)

ICV microinjection of a low dose of IL-1 β (10 pg/animal) induces hyperalgesia for a noxious heat stimulus and co-injected *a*-MSH completely abolishes this response. Also, injection of the high dose of 100 ng/animal IL-1 β does not induce hyperalgesia.

Fos expression in the PVN (Fig 6, 7, 8)

After injecting such a hyperalgesic dose of IL-1 β , the number of Fos-immunoreactive



Figure 7 Numerical density of Fos-positive neurons in the total PVN, 90 min after ICV-administration of saline (S), 10 pg/animal IL-1β (IL), 10 pg/ animal IL-1β+30 ng/animal a-MSH (IL+M) or 30 ng/animal a-MSH (M). N is indicated on top of each column. Means+S.E.M. * P≤0.001.



Figure 8 Numerical density of Fos-positive neurons in the PVN and its subregions, viz. the parvocellular area (parvo), medial, dorsal and lateral subregions of the parvo, and the magnocellular area (magno), 90 min after ICV-administration of saline, 10 pg/animal IL-1 β or 10 pg/animal IL-1 β +30 ng/animal *a*-MSH. Means+S.E.M, * P \leq 0.05, ** P \leq 0.001.

neurons increased in the PVN, especially in the medial part of the parvocellular region. This may mean that the PVN has not only a role in hyperalgesia but also in a second process. In view of the involvement of the PVN in the



Figure 9 Fos-positive neuronal nuclei (arrows) in the ARC, 90 min after ICV-administration of saline (a), 10 pg/animal IL-1 β (b; IL-1 β), 10 pg/animal IL-1 β+30 ng/animal a-MSH (c; IL-1 β+a-MSH) or 30 ng/animal a-MSH (d; a-MSH). Inset in b shows detail of Fospositive nuclei. Scale bar =50 μ m.

control of the hypothalamo-hypophyseal axis, this action may be related to a prolonged stressadaption response. Co-injection of *a*-MSH with a hyperalgesic dose of IL-1 β prevents induction of Fos-expression in the PVN. This result demonstrates that *a*-MSH can antagonize IL-1 β .

Fos expression in the ARC (Figure 9, 10)

The question arises as to the source of this a-MSH. Therefore we studied the ARC and the PI, both containing a-MSH-producing cells. Following ICV administration of a hyperalgesic dose of IL-1 β , Fos-induction was observed in the ARC but not in the PI, whereas the Fos-induction in the ARC was completely abolished by co-injected a-MSH. This fact suggests that the ARC rather than the PI is involved in antagonizing the hyperalgesic effect of IL-1 β .

Conclusion

This study provides evidence that ICV

S 206



Figure 10 Numerical density of Fos-positive neurons in the ARC, 90 min after ICV-administration of saline (S), 10 pg/animal IL-1β (IL), 10 pg/ animal IL-1β+ 30 ng/animal a-MSH (IL+M) or 30 ng/animal a-MSH (M). N is indicated on top of each column. Means+S.E.M. * P≤0.001.

injection of a hyperalgesic dose of IL-1 β activates both the PVN and the ARC, and that α -MSH produced in the ARC, but probably not in other parts of the brain and not in the pituitary gland, antagonizes this effect of IL-1 β , possibly by inhibiting PVN activity.

Acknowledgments

The authors wish to thank professors Hiroyuki Yaginuma and Takashi Kachi, and Drs Keiji Nishiyama and Seiji Watanabe for their supports.

References

- Jenks BG, Verburg-van Kemenade BML, Martens GJM. Pro-opiomelanocortin in the amphibian pars intermedia: a neuroendocrine model system. In: Hadley ME (ed). The Melanotropic Peptides. Vol 1. Source, synthesis, chemistry, secretion, circulation, and metabolism. CRC Press, Boca Raton, 1988;103-26.
- 2) Tonon MC, Danger JM, Lamacz M, Leroux P,

Adjeroud S, Anderson A, Verburg-van Kemenade BML, Jenks BG, Pelletier G, Stoeckel L, Burlet A, Kupryszewski G, Vaudry H. Multihormonal control of melanotropin secretion in cold-blooded vertebrates. In: Hadley ME (ed). The Melanotropic Peptides. Vol 1. Source, synthesis, chemistry, secretion, circulation, and metabolism. CRC Press, Boca Raton, 1988;127-70.

- 3) Eberle AN. Effects of MSH on pigment cells. In: Eberle AN (ed). The Melanotropins. Chemistry, physiology and mechanisms of action. Karger, Basel, 1988;210-52.
- 4) Jenks BG, Leenders HJ, Martens GJM, Roubos EW. Adaptation physiology: the functioning of pituitary melanotrope cells during background adaptation of the amphibian *Xenopus laevis*. Zool Sci 1993;10:1-11.
- 5) Vaudry H, Eberle AN (eds). The melanotropic peptides. Ann NY Acad Sci 1993;680:687pp.
- 6) Roubos EW. Background adaptation by Xenopus laevis: a model for studying neuronal information processing in the pituitary pars intermedia. Comp Biochem Physiol 1997;118:533-50.
- 7) Vaudry, H., M.C. Tonon, E.W. Roubos, Loof A de (eds). Trends in Comparative Endocrinology and Neurobiology. From Molecular to Integrative Biology. Ann NY Acad Sci 1998;839:750pp.
- 8) Vaudry H, Chartrel N, Desrues L, Galas L, Kikuyama S, Mor A, Nicolas P, Tonon MC. The pituitary-skin connection in amphibians. Reciprocal regulation of melanotrope cells and dermal melanocytes. Ann NY Acad Sci 1999;885:41-56.
- 9)Roubos EW, Scheenen WJJM, Jenks BG. Neuroendocrinology, from concepts and complexity to integration - the Xenopus pars intermedia. In: Goos HJTh, Rastogi RK, Vaudry H, Pierantoni R (eds): Perspective in Comparative Endocrinology. Monduzzi Editore, Bologna 2001;465-72.
- 10) Roubos EW, Scheenen WJJM, Cruijsen PMJM, Cornelisse LN, Leenders HJ, Jenks BG. New aspects of signal transduction in the Xenopus laevis melanotrope cell. Gen Comp Endocrinol 2002;126:255-60.
- 11) Kolk SM, Kramer BMR, Cornelisse LN, Scheenen WJJM, Jenks BG Roubos EW. Multiple control and

dynamic response of the Xenopus melanotrope cell. Comp Biochem Physiol B 2002;132:257-68.

- 12)Kramer BMR, Cruijsen PMJM, Ouwens DTWM, Coolen MW, Martens GJM, Roubos EW, Jenks, BG. BDNF acts as an autocrine factor on pituitary melanotrope cells of Xenopus laevis. Endocrinology 2002;143:1337-45.
- 13)Kramer BM, Song JY, Westphal NJ, Jenks BG, Roubos EW. Regulation of neurons in the suprachiasmatic nucleus of Xenopus laevis. Comp Biochem Physiol B Biochem 2002;132:269-74.
- 14) Tuinhof R, Laurent FY, Ebbers RG, Smeets WJJA, Van Riel MC, Roubos EW. Immunocytochemistry and in situ hybridization of neuropeptide Y in the hypothalamus of Xenopus laevis in relation to background adaptation. Neuroscience 1993;55: 667-75.
- 15) Tuinhof R, Artero C, Fasolo A, Franzoni MF, Ten Donkelaar HJ, Wismans PG, Roubos EW. Involvement of retinohypothalamic input, suprachiasmatic nucleus, magnocellular nucleus and locus coeruleus in control of melanotrope cells of Xenopus laevis: a retrograde and anterograde tracing study. Neuroscience 1994;61:411-20.
- 16)Kramer BM, Welting J, Berghs CA, Jenks BG, Roubos EW. Functional organization of the suprachiasmatic nucleus of Xenopus laevis in relation to background adaptation. J Comp Neurol 2001;432:346-55.
- 17) Tonosaki Y, Nishiyama K, Honda T, Ozaki N, Sugiura Y. D2-like dopamine receptor mediates dopaminergic or gamm-aminobutyric acidergic inhibition of melanophore-stimulating hormone release from the pars intermedia in frogs (Rana nigromaculata). Endocrinology 1995;136:5260-5
- 18) Fernandez PJ, Bagnara JT. Effect of background color and low temperature on skin color and circulating *a* -MSH in two species of leopard frog. Gen Comp Endocrinol 1991;83:132-41.
- 19) Hadley ME, Bower SA. Metabolic requirements for melanophore-stimulating hormone (MSH) secretion. Gen Comp Endocrinol 1976;28:118-30.
- 20) Ubink R, Jenks BG, Roubos EW. Physiologically induced Fos expression in the hypothalamohypophyseal system of Xenopus laevis.

Neuroendocrinology 1997;65:413-22.

- 21) Morgan JI, Curran T. Stimulus-transcription coupling in the nervous system: involvement of the inducible proto-oncogenes fos and jun. Annu Rev Neurosci 1991;14:421-51.
- 22) Dube D, Lissitzky JC, Leclerc R, Pelletier G. Localization of alpha-melanocyte-stimulating hormone in rat brain and pituitary. Endocrinology 1978;102:1283-91.
- 23) Eberle AN. MSH in the central nervous system. In: Eberle AN (ed). The melanotropins. Chemistry, physiology and mechanisms of action. Karger, Basel, 1988;158-69.
- 24) Inagaki S. Hypothalamus. In Tohyama M, Shioya Y (ed). Chemical neuroanatomy. Koseisha, Osaka, 1987;167-216 (Japanese).
- 25)Tonosaki Y, Cruijsen PMJM, Nishiyama K, Yaginuma H, Roubos EW. Low temperature stimulates a-MSH secretion and inhibits background adaptation in Xenopus laevis. J Neuroendocrinol 2004;16:894-905.
- 26) Hogben L, Slome D. The pigmentary effector system. VI. The dual character of endocrine coordination in amphibian colour change. Proc R Soc Lond B 1931;108:10-52.
- 27) Eberle AN. Bioassays for MSH and MCH In: Eberle AN (ed). The Melanotropins. Chemistry, physiology and mechanisms of action. Karger, Basel 1988;88-127.
- 28) Rijk, EPCT de, Jenks BG, Wendelaar Bonga SE. Morphology of the pars intermedia and the melanophore stimulating cells in *Xenopus leavis* in relation to background adaptation. Gen Comp Endocrinol 1990;79:74-82.
- 29) Burgers ACJ, Imai K, Oordt GJ van. The amount of melanophore-stimulating hormone in single pituitary gland of Xenopus laevis kept under various conditions. Gen Comp Endocrinol 1963;3:53-7.
- 30) Tonosaki Y, Cruijsen PMJM, Nishiyama K, Yaginuma H, Roubos EW. Regulation of *a*-MSH release from the pituitary pars intermedia of *Xenopus laevis* in a cold environment. In Perspective in Comparative Endocrinology, Goos HJTh, Rastogi RK, Vaudry H, Pierantoni R (eds), Monduzzi

S 208

Editore, Bologna, 2001;821-6.

- 31) Tonosaki Y, Nishiyama K, Roubos EW, Sugiura Y. α -MSH antagonizes interleukin-1 β -induced hyperalgesia and Fos-expression in the paraventricular and arcuate nucleus of the rat. Neuroendocrinology. 2005;81:167-73.
- 32)Hori T, Oka T, Hosoi M, Abe M, Oka K. Hypothalamic mechanisms of pain modulatory actions of cytokines and prostaglandin E2. Ann N Y Acad Sci 2000;917:106-20.
- 33) Tatro JB, Sinha PS. The central melanocortin system and fever. Ann N Y Acad Sci 2003;994: 246-57.
- 34) Eberle AN. Effects of the immune system. In: Eberle AN (ed). The melanotropins. Chemistry, physiology and mechanisms of action. Karger, Basel, 1988;266-8.
- 35) Oka T, Aou S, Hori T. Intracerebroventricular injection of interleukin-1 beta induces hyperalgesia in rats. Brain Res 1993;624:61-8.
- 36)Oka T, Aou S, Hori T. Intracerebroventricular injection of interleukin-1 beta enhances nociceptive neuronal responses of the trigeminal nucleus caudalis in rats. Brain Res 1994;656:236-44.
- 37) Tonosaki Y, Sugiura Y. *a*-MSH modulates Fos expression in the paraventricular nucleus and hyperalgesia induced by intracerebroventricular administration of interluekin-1 β in rats. Ann N Y Acad Sci 1998;839:615-8.
- 38) Rivest S, Torres G, Rivier C. Differential effects of central and peripheral injection of interleukin-1 beta on brain c-fos expression and neuroendocrine functions. Brain Res 1992;587:13-23.

- 39) Rivest S, Rivier C. Interleukin-1 beta inhibits the endogenous expression of the early gene c-fos located within the nucleus of LH-RH neurons and interferes with hypothalamic LH-RH release during proestrus in the rat. Brain Res 1993;613:132-42.
- 40) Chang SL, Patel NA, Romero AA, Thompson J, Zadina JE. Fos expression induced by interleukin-1 or acute morphine treatment in the rat hypothalamus is attenuated by chronic exposure to morphine. Brain Res 1996;736:227-36.
- 41)Chang SL, Ren T, Zadina JE. Interleukin-1 activation of Fos proto-oncogene protein in the rat hypothalamus. Brain Res 1993;617:123-30.
- 42) Day HE, Akil H. Differential pattern of c-fos mRNA in rat brain following central and systemic administration of interleukin-1-beta: implications for mechanism of action. Neuroendocrinology 1996;63:207-18.
- 43) Tonosaki Y, Nishiyama K, Yaginuma H, Sugiura Y. *a*-MSH modulates Fos expression in paraventricular nucleus of hypothalamus induced by interleukin-1β in rats. In Advances in Comparative Endocrinology. Kawashima S, Kikuyama S (eds), Monduzzi Editore, Bologna, 1997;1027-32.
- 44) Sekiguchi Y, Konnai Y, Kikuchi S, Sugiura Y. An anatomic study of neuropeptide immunoreactivities in the lumbar dura mater after lumbar sympathectomy. Spine 1996;21:925-30.
- 45) Honda T, Oda S, Ozaki N, Tonosaki Y, Nishiyama K, Sugiura Y. Neuronal damage of the primary afferent neurons elicits Fos expression even in spinal dorsal horn of the capsaicin-induced analgesic rats. Pain Res 1995;10:61-70.